Drug firms such as Abbott Healthcare, Ipca Laboratories and Merck would be impacted by National Pharmaceutical Pricing Authority's (NPPA) move.
The prices of six formulation packs have been fixed/ revised under Drug Price Control Order (DPCO), 2013, NPPA said in a statement.
Earlier this month, the NPPA had capped the prices of 18 formulation packs, including anti-diabetic Metformin HCl tablets, anti-bacterial Ceftriaxone Sodium injection packs and devices among others.
At present, the government caps prices of essential drugs based on the simple average of all medicines in a particular therapeutic segment with sales of more than 1 per cent.
The government had notified DPCO, 2013, which covers 680 formulations, effective May 15, 2014, replacing the 1995 order that regulated only 74 bulk drugs.